Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY – Get Free Report) was the target of a large decline in short interest in the month of October. As of October 15th, there was short interest totaling 19,178 shares, a decline of 81.8% from the September 30th total of 105,501 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average trading volume of 224,827 shares, the days-to-cover ratio is currently 0.1 days.
Daiichi Sankyo Price Performance
DSNKY stock opened at $17.91 on Tuesday. Daiichi Sankyo has a 52-week low of $14.98 and a 52-week high of $26.80. The stock’s fifty day simple moving average is $17.82 and its 200-day simple moving average is $17.79. The company has a quick ratio of 1.96, a current ratio of 2.92 and a debt-to-equity ratio of 0.29. The stock has a market capitalization of $33.37 billion, a price-to-earnings ratio of 20.83, a price-to-earnings-growth ratio of 1.90 and a beta of -0.11.
Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) last released its earnings results on Friday, July 31st. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The company had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.32 billion. Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.35%. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. Equities research analysts expect that Daiichi Sankyo will post 0.93 EPS for the current year.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently issued reports on DSNKY shares. Jefferies Financial Group downgraded shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research report on Thursday, July 30th. Zacks Research cut Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 20th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Reduce”.
View Our Latest Stock Analysis on DSNKY
Daiichi Sankyo Company Profile
Daiichi Sankyo Co, Ltd. is a Japan-based global pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses primarily on oncology, with additional activities in areas such as cardiovascular disease, rare diseases and other specialty therapies. Its products are marketed in Japan and internationally through subsidiaries, partnerships and licensing agreements.
Daiichi Sankyo is particularly known for its antibody-drug conjugate technology, which is designed to deliver cancer-killing agents more selectively to tumor cells.
Read More
- Five stocks we like better than Daiichi Sankyo
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Daiichi Sankyo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daiichi Sankyo and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
